Not on its own, at the time of writing, because Bangladesh is not a PCT contracting state and PCT applicants must include at least one national or resident of a contracting state. Bangladeshi groups sometimes file through a genuine foreign subsidiary, or alongside a foreign co-applicant such as a research partner. That can work, but the right to apply must be properly assigned and the ownership structure should suit later licensing and tax. Where the PCT is not available, direct national filings within the Paris Convention priority year remain an effective international patent filing route.

No. A PCT application cannot designate Bangladesh, so there is no PCT national phase here. To obtain a Bangladesh patent, the applicant must file a national application at the DPDT under the Bangladesh Patent Act 2023. If an earlier application was filed in another Paris Convention country, the Bangladesh application can claim that priority if it is filed within twelve months of the first filing. Foreign technology owners manufacturing or selling here should diarise that date carefully, because missing it can mean that their own later filing lacks novelty. We usually prepare it in parallel with the PCT application.

Possibly, but the position must be checked quickly. Most patent systems require absolute novelty, meaning any public disclosure before filing can count against the application. Some countries allow a limited grace period for the inventor's own disclosure, but the rules and time limits differ, and relying on them is risky. We review exactly what was disclosed, when, where and to whom, and identify which markets may still be available. Going forward, the safest course is to file before any presentation and to use confidentiality agreements for all investor and partner discussions. Our first call usually maps which markets remain open.

Costs depend on the number of countries, the length and complexity of the specification, translation requirements and how prosecution goes, so there is no standard figure. The largest expense usually arises at the national phase and during examination in each country, rather than at the first filing. The PCT route can defer those costs while the commercial case develops. We prepare a staged budget showing when each cost falls, so that management or investors can decide market by market whether to continue, rather than commit to a worldwide programme at the outset. Early choices drive international patent filing costs.

Ownership depends on the employment or research contract, the law of the place of employment and any funding or collaboration terms. Employee inventions often belong to the employer where the work falls within the employee's duties, but this should not be assumed, particularly for consultants, students, visiting researchers or staff working across group companies. Patent offices may require evidence of the applicant's right to apply. We review the documents, prepare assignments where needed and agree fair arrangements for inventors so that the international patent filing programme rests on secure title. Disputed title can stall a filing for months.

The Bangladesh Patent Act 2023 excludes certain subject matter from patent protection, and computer programs and business methods as such are commonly excluded in many systems. A software-related invention that solves a technical problem in a technical way may still be patentable in some jurisdictions, but approaches differ between Bangladesh, Europe, the US, India and other offices. We work with patent attorneys to assess each market. Where patent protection is uncertain, copyright, confidentiality and well-drafted licence terms often provide more reliable protection for software. International patent filing for software needs a market-by-market view, weighing patents against copyright and confidentiality.

As a least developed country, Bangladesh has relied on WTO transition arrangements that limit the obligation to grant and enforce pharmaceutical patents. Graduation from LDC status changes that position, and the government has been reviewing the law and practice in response. Pharmaceutical companies, both local manufacturers and foreign originators, should review product pipelines, licensing and filing strategy now rather than wait. Because the transition details continue to evolve, we advise on the position at the time of each decision and coordinate with regulatory and international patent filing counsel abroad. Timing matters for international patent filing here.

For most PCT contracting states, national phase entry is due 30 months from the earliest priority date, and some offices allow 31 months or more. Missing the deadline can be fatal in some countries, while others allow limited reinstatement. We start the decision process several months before the deadline, review the international search report and written opinion, update the commercial evidence and confirm costs, so that the client decides deliberately rather than under time pressure. Bangladesh is not part of this timetable, which is why its separate filing deadline must be diarised. We diarise both from the first instruction.